Optimizing Cardiovascular Health: Advancements in LDL Cholesterol Management through Intensive and Early Treatment Strategies : Episode 4

Opinion

Video

May 8, 2024

Innovations in Small Interfering RNA (siRNA) Therapy

Author(s):

Pam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC

Leading experts highlight the established role of PCSK9 inhibitors, such as evolocumab and alirocumab, and introduce the promising second-generation PCSK9 inhibitors, known as small interfering RNA (siRNA), which represent an innovative therapeutic approach that selectively reduces the production of specific proteins through RNA interference.

EP: 1.Overview of Low-Density Lipoprotein Cholesterol Management

EP: 2.Stricter LDL-C Targets: Explaining Goalpost Changes to Patients

EP: 3.Ongoing Lp(a) Trials and Clinical Approaches to Treatment

EP: 4.Innovations in Small Interfering RNA (siRNA) Therapy

EP: 5.Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data

EP: 6.Evaluating Safety of Novel LDL Management Mechanism

EP: 7.Examining Results from VICTORION-INITIATE Trial

EP: 8.Other Notable Emerging Lipid-Lowering Treatments

EP: 9.REDUCE-IT Trial and Triglyceride-Lowering Agents

EP: 10.Diabetes, GLP-1, and Lipid Reduction

EP: 11.Medication Adherence in Patients with High LDL Cholesterol

EP: 12.Overcoming Prior Authorization Barriers in LDL Cholesterol Therapies

EP: 13.Cardiometabolic Medicine: Seeing the Patient as a Whole

Related Videos

Gregory Mattingly, MD I St. Charles Psychiatric Associates

Duloxetine for Patients with COPD Suffering from Comorbid Depression

Enhancing Standards for Ethical Responsibilities within Clinical Research

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.